TGFB1 and myelodysplastic syndrome: Together with the emergence of effective therapies for LR-MDS targeting disease-associated pathways and processes, e.g., involving transforming growth factor beta (TGF-β) signaling, DNA methylation, and other epigenetic targets, our understanding of the LR-MDS pathogenesis also advances [11].